A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin - Gray, J E; Infante, J R; Brail, L H (Investigational New Drugs., 2015)
et al.